News | November 05, 2008

Lantheus Welcomes New Consensus Statement on Echo Contrast Use

November 6, 2008 - Lantheus Medical Imaging Inc. welcomes the “Consensus Statement on the Clinical Applications of Ultrasound Contrast” released by the American Society of Echocardiography (ASE) published in the November issue of the Journal of the American Society of Echocardiography.

Developed by members of the U.S. echocardiography community, ASE’s consensus statement outlines when and how ultrasound contrast agents are to be used appropriately and efficiently to enhance the diagnostic capability of echocardiography.

“We applaud the American Society of Echocardiography for its leadership in addressing the effective use of contrast ultrasound by authoring the Contrast Consensus Statement guidance document for the echocardiography community. This important consensus statement speaks to the clinical relevance of contrast and guides clinicians towards a team-approach to care for effective contrast use,” said Don Kiepert, president and CEO, Lantheus Medical Imaging. “The release of this consensus statement serves to validate the clinical need of ultrasound contrast use in echocardiography and reinforces the important role contrast plays in clinical diagnosis, patient management and clinical research.”

ASE’s statement substantiates the established use of ultrasound contrast agents in diagnostic cardiovascular imaging in echocardiography and discusses the important role physicians, sonographers and nurses play in efficiently integrating the use of contrast agents into the echocardiography laboratory. Additionally, the document highlights the role of echocardiography contrast imaging agents in improving cardiac structural definition and outlines the clinical situations when non-enhanced imaging does not yield diagnostic information. Lantheus’ echocardiography contrast agent, DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension, is specifically indicated for the use of patients with suboptimal echocardiograms to opacify the left ventricular chamber. Although the consensus statement also discusses, among other things, the use of contrast agents in stress echocardiography, the safety and efficacy of DEFINITY with exercise stress or pharmacologic stress testing have not been established, the company said.

The recommendations are based on a critical review of the existing medical literature, including prospective clinical trials, and when no significant study data were available, expert consensus opinion. The statement also thoroughly reviewed the recent labeling changes by the FDA regarding ultrasound contrast agent use and safety information.

In May 2008, Lantheus announced the initiation of CaRES (Contrast Echocardiography REgistry for Safety Surveillance), a multi-center Phase IV observational study that will further evaluate the safety profile of DEFINITY in patients with suboptimal echocardiograms and provide safety information on the use of ultrasound contrast agents in routine clinical practice. The open-label, non-randomized registry is being conducted in more than 10 clinical sites in the U.S. and include at least 1,600 patients. The study will gather data on patient characteristics and demographics, indication for DEFINITY’s use, results of safety monitoring of patients during and after DEFINITY administration, and the nature and frequency of any adverse events that may occur.

The FDA issued a black box warning for echo contrast agents last fall, but this summer downgraded the level of warning. The FDA reports there have been some rare but serious cardiopulmonary reactions, including fatalities, during or following perflutren-containing microsphere administration. The FDA now requires clinicians to assess all patients for the presence of any condition that precludes echo contrast agent administration. In patients with pulmonary hypertension or unstable cardiopulmonary conditions, clinicians are supposed to monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after administration.

Lantheus said DEFINITY should not be administered to patients with known or suspected cardiac shunts (right-to-left, bi-directional or transient right-to-left), or hypersensitivity to perflutren. It also should not be administered by intra-arterial injection.

For more information: www.lantheus.com

Related Content

Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
New Vascular Ultrasound Registry Looks to Enhance Patient Care
News | Cardiovascular Ultrasound | January 17, 2018
The Society for Vascular Ultrasound (SVU), the Society for Vascular Surgery (SVS) and Medstreaming-M2S announced the...
Sponsored Content | Videos | Ultrasound Imaging | January 11, 2018
Mindray recently featured a new upgrade for its premium Resona 7 ultrasound system at the Radiological Society of North...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
New International Report Provides Comprehensive Guide to Imaging in Chagas Heart Disease
News | Cardiovascular Ultrasound | January 03, 2018
Chagas disease (ChD), an infectious parasitic disease transmitted primarily by triatomine insects, has become a...
Toshiba Medical Introduces New Entry-Level Aplio i600 Ultrasound Platform
News | Ultrasound Imaging | December 21, 2017
Toshiba Medical, a Canon Group company, showcased the Aplio i600, the newest addition to the premium Aplio i-series...
Bay Labs Completes $5.5 Million Series A Financing for AI-Driven Ultrasound
News | Cardiovascular Ultrasound | December 21, 2017
December 21, 2017 — Bay Labs, a medical technology company applying...
Videos | RSNA 2017 | December 20, 2017
ITN and DAIC Editor Dave Fornell takes a tour of some of the most interesting new medical imaging technologies on the
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
Overlay Init